TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 86.2%
Gross margin was 86.2% in Q1 FY2026, up 2.5 pp from a year earlier. On a trailing-twelve-month basis it was 85.1%, down 0.5 pp year over year. Over 3 fiscal years it widened by 2.8 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 84.6%
- Year-over-year change
- -1.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.6% | -1.5pp |
| FY2024 | 2024-12-31 | 86.1% | +0.1pp |
| FY2023 | 2023-12-31 | 85.9% | +4.1pp |
| FY2022 | 2022-12-31 | 81.8% | -4.0pp |
| FY2021 | 2021-12-31 | 85.8% | — |
Gross Margin vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 gross margin of 85.1% is the highest of the 11 companies compared; the peer median is 49.4%.
- Its year-over-year change of -0.5 pp is the 5th highest of 11, against a peer median of -1.8 pp.
- Over three fiscal years its change of +2.8 pp compares with a peer median of -8.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 85.1% | -0.5 pp | +2.8 pp | |
| LTM Mar 2026 | 80.7% | -0.2 pp | -7.3 pp | |
| LTM Mar 2026 | 72.2% | +1.7 pp | +604.5 pp | |
| LTM Mar 2026 | 71.1% | +4.4 pp | +25.6 pp | |
| LTM Mar 2026 | 58.3% | +12.7 pp | +25.3 pp | |
| LTM Mar 2026 | 50.9% | -1.4 pp | +17.0 pp | |
| LTM Mar 2026 | 48.0% | -15.6 pp | -27.8 pp | |
| LTM Mar 2026 | 45.3% | -2.1 pp | -10.0 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | 28.3% | -24.8 pp | -25.9 pp |
| LTM Dec 2025 | -98.2% | -3.3 pp | -18.0 pp | |
| LTM Mar 2026 | -489.8% | -407.5 pp | -290.8 pp | |
| Peer median (excluding TLSI) | 49.4% | -1.8 pp | -8.7 pp | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.